ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022
Anticoagulation and bleeding in the cancer patient.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Pooled it
- Antithrombotic Therapy After PCI in High-Risk Cardiovascular Patients: Navigating Complexity Beyond Guidelines.Journal of clinical medicine · 2026Review
- Assessment of Anti-Factor Xa Levels in Children Receiving Low-Molecular-Weight Heparin for Treatment and Prophylaxis.Children (Basel, Switzerland) · 2026Article
- Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges.Journal of thrombosis and thrombolysis · 2026Review
- Cytogenetic alterations and coagulopathy in breast cancer patients: molecular mechanisms and clinical implications.Annals of medicine and surgery (2012) · 2026Review
- Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.International journal of molecular sciences · 2026Review
- Tumor Characteristics and Clinical Features of the Patient as Prognostic Factors in PDAC.Cancers · 2025Review
- Long-term bleeding events post-percutaneous coronary intervention in patients with malignancy with and without anticoagulant therapy.Cardiovascular intervention and therapeutics · 2025Article
- Clinical Implications of Antidepressants and Associated Risk of Bleeding: A Narrative Review.Current pain and headache reports · 2025Review
- Current practices and challenges in the management of cancer-associated thrombosis: a survey of Italian oncologists.Frontiers in oncology · 2025Article
- Clear Cell Ovarian Carcinoma and Its Distinct Coagulopathy Profile: Molecular Drivers and Clinical Implications.Cancer management and research · 2025Review
- Clinical Care Pathway and Management of Major Bleeding Associated with Nonvitamin K Antagonist Oral Anticoagulants: A Modified Delphi Consensus from Saudi Arabia and UAE.Mediterranean journal of hematology and infectious diseases · 2024Review
- Hemoptysis in Cancer Patients.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Cancer patients have an increased risk of bleeding compared to non-cancer patients with anticoagulant therapy. A bleeding risk assessment before initiation of anticoagulation is recommended. Currently low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) are the mainstays of treatment for cancer-associated venous thromboembolism (VTE). Since DOACs are administered orally, they offer some convenience and ease of administration; however, LMWH may be preferred in certain cancers. Given the prevalence of anticoagulant therapies in cancer patients, clinical providers must be able to recognize potentially critical bleeding sites and modalities to reverse major hemorrhage. Reversal agents or antidotes to bleeding may be required when bleeding is persistent or life-threatening. These include vitamin K, fresh frozen plasma (FFP), protamine, prothrombin complex concentrate (PCC) or andexanet alfa, and idarucizumab. Inferior vena cava (IVC) filter insertion can be also considered in those with major bleeding. Evidence for timing and need for re-initiation of anticoagulant therapy after a major bleeding remains sparse, but a multi-disciplinary approach and shared decision-making can be implemented in the interim.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.